Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.
In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results